202 related articles for article (PubMed ID: 29058790)
1. Clinical and prognostic value of the C-Met/HGF signaling pathway in cervical cancer.
Boromand N; Hasanzadeh M; ShahidSales S; Farazestanian M; Gharib M; Fiuji H; Behboodi N; Ghobadi N; Hassanian SM; Ferns GA; Avan A
J Cell Physiol; 2018 Jun; 233(6):4490-4496. PubMed ID: 29058790
[TBL] [Abstract][Full Text] [Related]
2. C-Met as a potential target for the treatment of gastrointestinal cancer: Current status and future perspectives.
Bahrami A; Shahidsales S; Khazaei M; Ghayour-Mobarhan M; Maftouh M; Hassanian SM; Avan A
J Cell Physiol; 2017 Oct; 232(10):2657-2673. PubMed ID: 28075018
[TBL] [Abstract][Full Text] [Related]
3. Frequent hepatocyte growth factor overexpression and low frequency of c-Met gene amplification in human papillomavirus-negative tonsillar squamous cell carcinoma and their prognostic significances.
Kwon MJ; Kim DH; Park HR; Shin HS; Kwon JH; Lee DJ; Kim JH; Cho SJ; Nam ES
Hum Pathol; 2014 Jul; 45(7):1327-38. PubMed ID: 24810547
[TBL] [Abstract][Full Text] [Related]
4. Co-expression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer.
Toiyama Y; Yasuda H; Saigusa S; Matushita K; Fujikawa H; Tanaka K; Mohri Y; Inoue Y; Goel A; Kusunoki M
Int J Cancer; 2012 Jun; 130(12):2912-21. PubMed ID: 21796631
[TBL] [Abstract][Full Text] [Related]
5. Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma.
Zhao Y; Zhang J; Tian Y; Xue C; Hu Z; Zhang L
Drug Des Devel Ther; 2015; 9():4897-907. PubMed ID: 26345996
[TBL] [Abstract][Full Text] [Related]
6. Targeting the hepatocyte growth factor/Met pathway in cancer.
De Silva DM; Roy A; Kato T; Cecchi F; Lee YH; Matsumoto K; Bottaro DP
Biochem Soc Trans; 2017 Aug; 45(4):855-870. PubMed ID: 28673936
[TBL] [Abstract][Full Text] [Related]
7. The potential therapeutic and prognostic impacts of the c-MET/HGF signaling pathway in colorectal cancer.
Parizadeh SM; Jafarzadeh-Esfehani R; Fazilat-Panah D; Hassanian SM; Shahidsales S; Khazaei M; Parizadeh SMR; Ghayour-Mobarhan M; Ferns GA; Avan A
IUBMB Life; 2019 Jul; 71(7):802-811. PubMed ID: 31116909
[TBL] [Abstract][Full Text] [Related]
8. Quercetin inhibits HGF/c-Met signaling and HGF-stimulated melanoma cell migration and invasion.
Cao HH; Cheng CY; Su T; Fu XQ; Guo H; Li T; Tse AK; Kwan HY; Yu H; Yu ZL
Mol Cancer; 2015 May; 14():103. PubMed ID: 25971889
[TBL] [Abstract][Full Text] [Related]
9. HGF/MET pathway aberrations as diagnostic, prognostic, and predictive biomarkers in human cancers.
Moosavi F; Giovannetti E; Saso L; Firuzi O
Crit Rev Clin Lab Sci; 2019 Dec; 56(8):533-566. PubMed ID: 31512514
[TBL] [Abstract][Full Text] [Related]
10. MiR-206 inhibits HGF-induced epithelial-mesenchymal transition and angiogenesis in non-small cell lung cancer via c-Met /PI3k/Akt/mTOR pathway.
Chen QY; Jiao DM; Wu YQ; Chen J; Wang J; Tang XL; Mou H; Hu HZ; Song J; Yan J; Wu LJ; Chen J; Wang Z
Oncotarget; 2016 Apr; 7(14):18247-61. PubMed ID: 26919096
[TBL] [Abstract][Full Text] [Related]
11. Increased HGF Expression Induces Resistance to c-MET Tyrosine Kinase Inhibitors in Gastric Cancer.
Ahn SY; Kim J; Kim MA; Choi J; Kim WH
Anticancer Res; 2017 Mar; 37(3):1127-1138. PubMed ID: 28314274
[TBL] [Abstract][Full Text] [Related]
12. The HGF inhibitory peptide HGP-1 displays promising in vitro and in vivo efficacy for targeted cancer therapy.
Chen L; Li C; Zhu Y
Oncotarget; 2015 Oct; 6(30):30088-101. PubMed ID: 26254225
[TBL] [Abstract][Full Text] [Related]
13. MET/HGF pathway in multiple myeloma: from diagnosis to targeted therapy?
Gambella M; Palumbo A; Rocci A
Expert Rev Mol Diagn; 2015; 15(7):881-93. PubMed ID: 25967746
[TBL] [Abstract][Full Text] [Related]
14. Targeting HGF/c-MET Axis in Pancreatic Cancer.
Pothula SP; Xu Z; Goldstein D; Pirola RC; Wilson JS; Apte MV
Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33271944
[TBL] [Abstract][Full Text] [Related]
15. Tumor-stromal cell interaction under hypoxia increases the invasiveness of pancreatic cancer cells through the hepatocyte growth factor/c-Met pathway.
Ide T; Kitajima Y; Miyoshi A; Ohtsuka T; Mitsuno M; Ohtaka K; Koga Y; Miyazaki K
Int J Cancer; 2006 Dec; 119(12):2750-9. PubMed ID: 16998831
[TBL] [Abstract][Full Text] [Related]
16. The role of the hepatocyte growth factor/c-MET pathway in pancreatic stellate cell-endothelial cell interactions: antiangiogenic implications in pancreatic cancer.
Patel MB; Pothula SP; Xu Z; Lee AK; Goldstein D; Pirola RC; Apte MV; Wilson JS
Carcinogenesis; 2014 Aug; 35(8):1891-900. PubMed ID: 24876152
[TBL] [Abstract][Full Text] [Related]
17. CAF-derived HGF promotes cell proliferation and drug resistance by up-regulating the c-Met/PI3K/Akt and GRP78 signalling in ovarian cancer cells.
Deying W; Feng G; Shumei L; Hui Z; Ming L; Hongqing W
Biosci Rep; 2017 Apr; 37(2):. PubMed ID: 28258248
[TBL] [Abstract][Full Text] [Related]
18. miR-198 inhibits migration and invasion of hepatocellular carcinoma cells by targeting the HGF/c-MET pathway.
Tan S; Li R; Ding K; Lobie PE; Zhu T
FEBS Lett; 2011 Jul; 585(14):2229-34. PubMed ID: 21658389
[TBL] [Abstract][Full Text] [Related]
19. Pancreatic Stellate Cells Facilitate Perineural Invasion of Pancreatic Cancer via HGF/c-Met Pathway.
Nan L; Qin T; Xiao Y; Qian W; Li J; Wang Z; Ma J; Ma Q; Wu Z
Cell Transplant; 2019; 28(9-10):1289-1298. PubMed ID: 31161784
[TBL] [Abstract][Full Text] [Related]
20. Extracellular Matrix Influencing HGF/c-MET Signaling Pathway: Impact on Cancer Progression.
Noriega-Guerra H; Freitas VM
Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30352967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
